Company Information

  

Address: 5858 HORTON STREET, #455  
City: EMERYVILLE 
State: CA 
Zip Code: 94608 
Telephone: (510) 550-8300 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a pharmaceutical company committed to developing and commercializing central nervous system, or CNS, therapies that address specific clinical needs for people living with orphan and other CNS disorders. Our current primary area of therapeutic focus is epilepsy and related seizure disorders. We have worldwide development and commercialization rights to ZX008, our lead product candidate. ZX008 is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. Dravet syndrome is a rare and catastrophic form of pediatric epilepsy with life threatening consequences for patients and for which current treatment options are very limited. ZX008 has received orphan drug designation in the United States and the European Union (EU) for the treatment of Dravet syndrome. In January 2016, we received notification of Fast Track designation from the FDA, for ZX008 for the treatment of Dravet syndrome.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-3.38NAN/E
03/2017-3.21NAN/E
12/2016-2.77NAN/E
09/2016-2.29NAN/E
06/2016-2.21NAN/E
03/2016-1.82NAN/E
12/2015-1.94NAN/E
09/2015-3.50NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.12Total Liab/Total Assets0.48
Net Inc/Total Assets-0.30Total Liab/Inv Cap0.53
Net Inc/Inv Cap-0.34Total Liab/Comm Equity0.20
Pretax Inc/Net Sales-2.41Interest Coverage Ratio-23.65
Net Inc/Net Sales-2.42Curr Debt/Equity0.03
Cash Flow/Net Sales-2.53LTD/Equity0.16
SG&A/NetSales1.00Total Debt/Equity0.18
Asset Utilization   Liquidity  
Net Receivables Turnover4.13Quick Ratio5.56
Inventory Turnover2.32Current Ratio5.90
Inventory Day Sales0.01Net Rec/Curr Assets0.10
Net Sales/Work Cap0.29Inv/Curr Assets0.06
Net Sales/PP&E16.87  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 7.13 2.70 10.99 6.57
Cost of Goods Sold 8.24 2.49 5.92 6.25
Selling & Admin Exps 6.00 7.15 6.49 6.74
Operating Income -22.08 -21.10 -23.32 -16.71
Interest Exp 0.58 0.58 1.04 0.57
Pretax Income -22.47 -21.11 -23.63 -17.61
Other Income 0.18 0.57 0.73 -0.33
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -23.01 -21.31 -23.49 -17.00

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 65.76 80.11 91.55 109.87
Receivables - Total 4.68 1.03 12.58 6.52
Inventories - Total 2.23 9.10 7.05 9.41
Total Current Assets 78.81 98.82 119.91 135.28
Net Property, Plant & Equipment 0.46 0.71 1.71 8.36
Total Assets 190.00 209.34 231.51 255.84
Liabilities        
Accounts Payable 13.98 11.99 14.58 10.68
Debt in Current Liabilities 6.84 4.72 3.27 0.00
Total Current Liabilities 21.98 18.34 20.31 14.13
Long-Term Debt 15.76 17.63 18.82 21.85
Total Liabilities 110.52 108.22 110.75 113.92
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.03 0.03 0.03 0.03
Retained Earnings -489.54 -466.53 -445.22 -421.73
Treasury Stock NA NA NA NA
Total Stockholders' Equity 79.48 101.12 120.76 141.92
Total Liabilities and Stockholders' Equity 190.00 209.34 231.51 255.84

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -14.58 -11.42 -18.50 -17.95
Net Cash Provided by Investing Activities -0.01 -0.03 0.00 -0.00
Net Cash Provided by Financing Activities 0.24 0.00 0.18 0.03

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201244.33-47.39--
12/201333.01-80.86--
12/201428.958.59--
12/201527.1826.14-1.94
12/201628.85-69.71-2.77
Growth Rates-10.18----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1710021,61968.55




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.